Welcome to our dedicated page for Plus Therapeutics SEC filings (Ticker: PSTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Plus Therapeutics filings document the company’s CNS oncology pipeline, diagnostic commercialization and public-company governance. Recent Form 8-K disclosures cover REYOBIQ regulatory developments, financial results, executive appointments and compensatory arrangements, board composition, annual meeting mechanics and Nasdaq listing matters.
The filing record also describes capital-structure actions, including the company’s reverse stock split and related charter amendment, as well as proxy disclosures on director elections, shareholder proposals, executive compensation and governance procedures. These filings connect Plus Therapeutics’ radiopharmaceutical development, CNSide diagnostic business, common stock structure and risk-related corporate events within its SEC reporting framework.
PLUS THERAPEUTICS director Ronald Asbury Andrews exercised equity awards, acquiring additional common stock through RSU vesting. On July 1, 2026, 922 Restricted Stock Units converted into 922 shares of common stock at a stated price of $0.00 per share as part of his compensation. Following the transaction, he directly holds 922 shares of common stock and 2,764 Restricted Stock Units that represent rights to receive the same number of shares, vesting in four substantially equal quarterly installments beginning on July 1, 2026.
PLUS THERAPEUTICS, INC. director Kyle Guse exercised restricted stock units to acquire 922 shares of Common Stock at no cost. After the transaction, he directly holds 922 Common shares. A related RSU grant totaling 2,764 units remains outstanding and vests in four substantially equal quarterly installments beginning on July 1, 2026.
PLUS THERAPEUTICS director An van Es-Johansson reported the vesting of 922 Restricted Stock Units (RSUs), which were converted into an equal number of shares of Common Stock at a price of $0.00 per share. Following this transaction, the reporting person directly holds 922 shares of Common Stock.
The RSU grant vests in four substantially equal quarterly installments beginning on July 1, 2026, meaning this filing reflects a compensation-related derivative exercise rather than an open-market purchase or sale, with no shares disposed of in the transaction.
PLUS THERAPEUTICS, INC. Chief Executive Officer Marc H. Hedrick reported routine equity compensation activity as Restricted Stock Units vested into Common Stock. On July 1, 2026, RSU vesting resulted in the acquisition of 16,439 shares of Common Stock at an exercise price of $0.00 per share. Following these conversions, he directly holds 34,431 shares of Common Stock and 163,650 RSUs, which represent contingent rights to receive an equal number of shares. The RSU grants vest in twelve substantially equal quarterly installments beginning on October 1, 2025, April 1, 2026, and July 1, 2026.
Plus Therapeutics director Howard Clowes exercised restricted stock units into common shares as part of equity compensation. On this Form 4, he acquired 922 shares of Plus Therapeutics common stock through the conversion of restricted stock units at a stated price of $0.00 per share.
Following the transaction, Clowes directly holds 1,981 shares of common stock and 2,764 restricted stock units. Each RSU represents a contingent right to receive one common share, with vesting in four substantially equal quarterly installments beginning on July 1, 2026. This filing reflects routine equity incentive vesting rather than an open-market stock purchase or sale.
PLUS THERAPEUTICS director Richard J. Hawkins reported a compensation-related equity transaction involving 922 shares. On July 1, 2026, 922 Restricted Stock Units (RSUs) vested, each RSU converting into one share of PLUS THERAPEUTICS common stock at a price of $0.00 per share.
The filing shows Hawkins directly holding 1,529 shares of common stock after the transaction, along with 2,764 RSUs that remain outstanding. According to the footnotes, this RSU grant vests in four substantially equal quarterly installments beginning on July 1, 2026, highlighting that this is a scheduled equity award rather than an open‑market trade.
PLUS THERAPEUTICS, INC. Chief Financial Officer Andrew John Hugh MacIntyre Sims reported equity compensation-related transactions in the company’s common stock. On July 1, 2026, he exercised or converted derivative awards into a total of 2,985 shares of common stock at a stated price of $0.0000 per share, reflecting non-cash vesting of awards.
The filing shows his direct holdings of common stock at 9,941 shares after one of the transactions, with 28,522 restricted stock units (RSUs) remaining after another. Footnotes state that each RSU represents a right to one common share and that the RSU grants vest in twelve substantially equal quarterly installments beginning on October 1, 2025, April 1, 2026, and July 1, 2026, respectively. These transactions appear to be part of scheduled RSU vesting rather than open-market buying or selling.
Plus Therapeutics entered an Equity Distribution Agreement that permits it to sell up to $17,350,000 of common stock through an at-the-market offering with Canaccord Genuity as sales agent.
Shares will be sold from time to time under a Form S-3 shelf registration, with Canaccord earning a 3.0% commission on gross proceeds plus up to $75,000 of reimbursed expenses. Plus Therapeutics can choose when and if to sell, set minimum acceptable prices, and suspend or terminate the program. Net proceeds are intended for general corporate purposes and working capital.
Plus Therapeutics, Inc. filed a Pre-Effective Amendment No. 1 to its Registration Statement (File No. 333-296411) on June 5, 2026 to furnish a Form of Indenture as Exhibit 4.3. The amendment is exhibits-only; the prospectus, prospectus supplement and other parts of the registration statement remain unchanged.